• Tuotekuvaus

  This new volume, Advances in Drug Discovery and Targeted Therapy for Alzheimer’s Disease, offers a comprehensive exploration of the forefront of research and innovation in this vital area. The culmination of the collective efforts of leading academicians and researchers who are dedicated to unraveling the complexities of AD and devising targeted solutions, the volume covers novel drug targets, emerging therapeutic strategies, and the latest developments in drug discovery technologies that are shaping the future of AD treatment. The book delves into the multifaceted nature of AD, exploring recent breakthroughs in understanding its pathophysiology and the development of targeted interventions. The book is structured into several thematic sections, each of which addresses a different facet of AD research and therapy development. Together, these sections offer a holistic view of the challenges and opportunities that researchers face as they work toward new therapeutic strategies. The volume first covers the complex pathophysiology of AD, offering insights into the molecular and cellular mechanisms underlying the disease, presenting the latest research on classical targets such as acetylcholinesterase, monoamine oxidases, and amyloid-beta plaques. It discusses why conventional treatments have fallen short and highlights the need for new therapeutic strategies. The volume goes on to focus on cutting-edge therapeutic approaches that are revolutionizing the field of Alzheimer’s drug discovery. The Tau protein, implicated in neurofibrillary tangles, NMDA blockers for modulating excitotoxicity, CDK5 for its involvement in Tau hyperphosphorylation, and Caspases as mediators of apoptosis, are explored in detail. By addressing these nonclassical but critical targets, the focus is on how these innovations are accelerating the discovery of novel compounds with the potential to alter the course of AD. Chapters also cover the novel mechanistic approaches leading to the development of targeted therapies that address specific aspects of AD pathology, reviewing emerging strategies such as a FAAH-ChE based multifunctional ligand strategy, which offers dual-target solutions and immunotherapy. The book also emphasizes the role of synaptogenesis in maintaining cognitive function and highlights natural products as promising neuroprotective agents. These cutting-edge strategies collectively represent the forefront of AD research, aiming to provide comprehensive and effective management solutions for this challenging condition. Bringing together diverse expertise and perspectives that reflect the multifaceted nature of AD research, the volume provides a deep understanding of Alzheimer’s drug discovery. The insights shared within these will stimulate further research and dialogue among researchers, clinicians, and pharmaceutical professionals dedicated to combating Alzheimer’s disease. It will be a valuable resource for postgraduate students, research scholars, professors, researchers in the pharmaceutical and biotechnology fields, and healthcare professionals specializing in neurosciences, including Alzheimer’s disease and related dementias.

• Tuotetiedot

  • Kustantaja / Valmistaja Apple Academic Press Inc.
  • ISBN 9781779642677
  • Vuosi 2026
  • Tuotekoodi 9781779642677
  • Leveys (mm) 152
  • Pituus (mm) 229
  • Kieli Englanti
  • Toimittanut Rati Kailash Prasad Tripathi
  • Sivumäärä 354
  • Tuotelinja Kirjat
  • Tuoteryhmä Ulk terveys (lääket, eläinlääk)
  • Tuotemuoto Kovakantinen
  • Ilmestymispäivä 24.11.2026
  • Tuotepääryhmä Ulkomaiset tietokirjat
  • Tuoteturvallisuusyhteystiedot Taylor & Francis Verlag GmbH, GPSR@taylorandfrancis.com, Kaufingerstraße 24, 80331 München, Germany, 80331, München
  • Thema-luokitus Lääketieteellinen tutkimus; Farmakologia; Alzheimerin tauti ja dementia; Farmaseuttinen kemia ja teknologia
  • ALV 13,5%

Tämä tuote kuuluu tuoteryhmiin